Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

May 14, 2024

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 64 min

Earnings Call Speaker Segments

Jost Reinhard

executive
#1

Good afternoon, and good morning to everyone. Thanks so much for being with us on our earnings call covering the first quarter of 2024. Bill is going to kick off the presentations today by sharing his view of how our business is developing and the progress we've made toward our strategic objectives. After that, Wolfgang will go into more detail on group and divisional performance and will comment on the outlook for the full year. Then we'll hold our Q&A session together with the presidents of our three divisions. Before we begin, I'd like to briefly point you to the cautionary language contained in our safe harbor statement. With that, Bill, over to you.

Bill Anderson

executive
#2

Thanks, Jost, and I appreciate everyone being with us today for the presentation of our first-quarter 2024 results. We're holding this call roughly 70 days on from the comprehensive strategic update we gave in March. So my remarks today will concentrate on how we performed, the headway we've achieved across each of the focus areas we laid out at Capital Markets Day, and what our priorities are as we move ahead. I believe that leaves us ample time for questions. Let me begin with the Q1 financial performance. Sales reached EUR 13.8 billion, and on a currency- and portfolio-adjusted basis — the basis I'll use throughout my remarks — that leaves us a touch under Q1 of last year. Core earnings per share came to €2.82, which is likewise slightly lower than a year earlier. And our free cash flow was -EUR 2.6 billion. That's better than Q1 of last year, mainly because litigation payouts were lower. All in all, this outcome matches what we expected, and we are reaffirming our 2024 outlook at constant currencies. Wolfgang will walk through the financial performance in greater detail shortly, but I want to highlight a few positives and some headwinds we encountered in Q1.

Bill Anderson

executive
#3

To start with the main points: in Crop Science, we beat every one of our competitors when it came to the sales trajectory, and that happened in a market environment that was very challenging. Our corn platform worldwide posted 2% growth, even though acreage declined in North America and Latin America. Global price increases gave that growth a boost, and they were driven by how the 240 new corn hybrids we brought to market last year performed. Turning to Pharmaceuticals, the launch medicines Nubeqa and Kerendia drove our top line growth. Eylea also delivered gains across every region, and we booked the first sales of Eylea 8 mg after the initial approvals. In Consumer Health, our dermatology category kept up its impressive growth trajectory. A great deal of that growth can be traced to innovation and geo expansion. We are now applying that same approach to our digestive health business. The great work I see behind these efforts encourages me. As you know, we also have some headwinds to manage. In Crop Science, glyphosate volumes were strong, but lower prices hurt our profitability. Within the division's core business, crop protection volumes came in lower, particularly in Europe, Middle East, and Africa. In Pharmaceuticals, our team actually managed a slight increase in Xarelto sales in Q1, but we are seeing additional pressure from generics in some markets like Canada.

Bill Anderson

executive
#4

And then currency headwinds hit our bottom line in each of the three divisions, with Consumer Health feeling it most. So although we are never happy about declines, considering how the market behaved — especially in agriculture — I'd say the teams stayed focused in Q1. That makes me proud, and I have confidence in what we can achieve this year. Beyond those figures, plenty happened that wasn't yet visible in our numbers. Back in March, I laid out four areas we're concentrating on to put Bayer back on track. Two months on, progress has been made in every one of them. On growth and innovation, in Pharma, elinzanetant has produced consistently positive top-line results across all 3 late-stage trials. The first data from the OASIS program will be presented this Friday at the annual ACOG meeting, and our work to secure first market authorizations is moving ahead at full speed. Another first-quarter highlight was the in-licensing of acoramidis from BridgeBio. That's an exciting opportunity for us, and we've begun preparing to launch this very important medicine in 2025. Expect further updates from us as the next milestones draw near. In Crop Science, we're extending our leading position. Thanks to all the new innovation we're bringing to market — including hundreds of new hybrids and seed varieties, plus several new crop protection formulations — we managed to outperform our peers in the first quarter.

Bill Anderson

executive
#5

We just recently reached an agreement with AlphaBio Control. Through this deal, we hold exclusive marketing rights for the first-ever biological insecticide aimed at arable crops. Over in Consumer Health, we brought Iberogast to the United States last month. This trusted product came into our portfolio in 2013, and since then we've grown it across many countries in Europe and beyond. I've actually been a customer myself in the past. Now, tens of millions of Americans who deal with occasional digestive health issues have the opportunity to benefit from Iberogast too. Turning to litigation, roughly two weeks ago, a Washington State court ruled in our favor, fully overturning a $185 million verdict. That's a significant win given its potential implications, since the errors the court identified matter for all of the Sky Valley Education Center trials and verdicts. So what happened in this case? First, the court rejected a substantial portion of the key plaintiff's expert's testimony on exposure. That ruling affects both prior and future trials. The court's decision determined that this testimony, I quote, "Was unreliable, untested, or junk science." Second, the court determined that the company had been improperly barred from presenting an important legal defense argument — a critical error that recurred in many of the trials that followed.

Bill Anderson

executive
#6

The plaintiffs are likely to file an appeal. Even so, we hold a strong conviction that what the appellate court ruled on those 2 points aligns closely with the law that applies here. Turning now to glyphosate. Whether we're in court or outside it, this matter sits at the very top of our agenda, since it extends well beyond our own company. Any threat to a sustainable supply of glyphosate carries enormous consequences for how we operate, and equally for U.S. agriculture, for food prices, and for our planet. Farmers throughout the United States understand this, and they are worried. That is the reason more than 80 groups have signed on to the Modern Ag Alliance, a coalition seeking to have U.S. agriculture governed by science-based law rather than by the litigation industry. To put it plainly, we want legislators to hear what the American farmer has to say. On top of that, we are exploring new approaches to tackle this danger to our operations, weighing carefully and with urgency what path serves U.S. farmers, U.S. consumers, our employees, and you best. Moving on to cash. Fewer than three weeks ago, at Bayer's annual stockholders meeting, 99% of voters backed our dividend proposal. We thank you for that overwhelming endorsement of this difficult step. It will assist us in deleveraging and in addressing the company's financial health.

Bill Anderson

executive
#7

Past this choice, Wolfgang will spend a few minutes underscoring how we've sharpened our attention to converting cash. And last, dynamic shared ownership. I'll cover the overall effect on our operations more fully on the upcoming slide, but right now I'd like to zero in on the organizational shifts we have implemented. The new organizational blueprints for both Crop Science and Pharmaceuticals have already been made public by those teams. Julio stepped into the Consumer Health role 2 weeks ago, and that group is building its structure quickly and with clear priorities. We are merging positions, crafting teams to deliver greater impact, and removing tiers — a great many tiers. Our senior leadership circle is already markedly smaller today than 1 year ago. During the first quarter by itself, we cut 1,500 roles. Roughly two-thirds of those positions were management jobs. We are aiming for EUR 500 million in sustainable cost savings in 2024 and EUR 2 billion in 2026, and our attention is fixed on getting there. We will keep updating you each quarter so you have clarity on how the organization is advancing. Yet the truest gauge of what we achieve will reach well beyond a headcount figure or a cost-reduction goal. In every part of Bayer, teams are operating under the new model.

Bill Anderson

executive
#8

Across North America and Latin America — our two biggest regions in Crop Science — every one of our customer teams is now operating under dynamic shared ownership. A substantial share of our manufacturing footprint already runs fully in DSO, and those sites are scaling it across the entire network at full speed. Altogether, that adds up to over 250 customer and product teams in Crop Science alone. These teams are owning their work in a completely new manner, deciding faster and better with the grower at the center of those decisions, which moves our business forward and drives innovation. More than 180 teams are up and running in our Pharmaceuticals division, among them the teams fueling growth and market access behind launches such as Nubeqa, Kerendia, and Eylea 8 mg. In Consumer Health, over 90 teams are activated around the globe. They are reporting gains in decision-making, supply capacity, and innovation delivery. We are going at full speed. The count of customer and product teams has grown 10x in only five months, and before the year is out, DSO will have rolled out to every part of Team Bayer. It has certainly been an eventful beginning to the year at Bayer.

Bill Anderson

executive
#9

A great deal of change is in motion right now, and for a big organization that can pull attention in many directions. Even so, every day I take inspiration from how committed our people are to the mission and from their determination to keep producing a better outcome. That is exactly why I have no doubt that Bayer has plenty of wins ahead, in this year and in the years that follow. Anyone tracking European soccer will be aware that, when it comes to winning at the moment, this company counts some rather impressive role models among its ranks. In any top European league, Bayer 04 Leverkusen now holds the all-time record for the longest unbeaten run of games, and it claimed the Bundesliga title along the way. Our colleagues at Bayer 04 make us extremely proud. What they have achieved proves the point. Get the right team and the right system, add plenty of focus and hard work, and over time it pays off... And as we concentrate on guiding Bayer toward consistent winning results, one quarter after another, we are glad to draw on their example. In that spirit, before I hand things over to Wolfgang, allow me to leave you with a few priorities that will shape Bayer over the coming months. Where innovation is concerned, you should look for progress to come from our pipelines and from our products that are in the launch phase.

Bill Anderson

executive
#10

Our Pharmaceuticals group anticipates results from Kerendia's initial phase III heart failure study and Nubeqa's ARANOTE trial quite shortly. Working alongside U.S. farmers, our Crop Science group is moving toward commercial launch of the Preceon Smart Corn System, which uses short stature corn — a genuine game changer that could reach over 220 million acres worldwide. Just to put that in perspective, 220 million acres equals France plus Germany combined. The impact will be tremendous. What we learn here applies directly to the full-scale rollout of the biotech variant of this technology. We expect that in 2027. Our Consumer Health group is concentrating on boosting launch effectiveness so we capture the full value of the science, such as Iberogast, that we are delivering to the consumer market. Beyond what the slide shows, we keep delivering on our priorities. A small group of people and myself are still weighing our options regarding the litigation front. We remain strongly focused on generating cash, meeting our targets, and achieving our longer-term ambition. Lastly, everyone across all of team Bayer is fully engaged in rolling out Dynamic Shared Ownership. Many thanks. I'll look forward to your questions shortly, but for now let me hand things to Wolfgang for more detail on our performance.

Wolfgang Nickl

executive
#11

Thanks, Bill, and greetings from my side as well. I want to give you some additional detail on what drove our results in the first quarter. Our financial numbers landed pretty much where we anticipated. Adjusted for currency and portfolio effects, Q1 sales were a touch under the previous year, off 1%. As reported, though, we posted a 4% decrease, and roughly EUR 500 million of foreign exchange headwinds accounted for that. Turning to earnings, EBITDA before special items reached EUR 4.4 billion, which is 1%, or roughly EUR 60 million, lower than the prior quarter. Two big effects came into play that mostly offset one another: a drop in Crop Science profitability, which stems mainly from softer glyphosate pricing, and a positive reconciliation result stemming from reduced long-term incentive provisions. We also faced about EUR 200 million of FX headwinds within EBITDA before special items. Core earnings per share amounted to EUR 2.82, which was EUR 0.30, or EUR 13, or 4%, under the same period a year earlier, largely due to higher interest payments and FX effects in the core financial result. That core financial result matches our modeling assumptions of approximately -EUR 2.3 billion for the full year. Free cash flow came in at -EUR 2.6 billion.

Wolfgang Nickl

executive
#12

Consistent with the crop business cycle, our first quarter showed negative cash flow. Even so, it was EUR 1.5 billion better than a year ago. The main factor was reduced litigation-related payouts for PCB. On top of that, the organization is laser focused on boosting earnings conversion into cash and on actively managing the company's working capital. Already our Q1 free cash flow contains positive results from our inventory initiatives. By the close of Q1, net financial debt had risen to EUR 37.5 billion, consistent with the seasonal pattern of our cash flow profile. Appreciation of the U.S. dollar also affected the debt level. As we introduced at the Capital Markets Day, additional information on reported earnings, on cash flow, and on divisional cost lines appears in the appendix to this presentation. Let's now pivot and examine divisional performance. When I talk about sales growth, I mean currency and portfolio-adjusted figures. Crop science sales reached EUR 7.9 billion in the first quarter, a decline of 3% versus the prior year. Our core business fell by 3%, which includes different effects. Adverse weather conditions, delayed protection purchases, and competitive pricing pressures weighed on our fungicides and other herbicide sales volumes in EMEA.

Wolfgang Nickl

executive
#13

Even so, growth in our corn business helped offset part of that, with average prices worldwide up 6%, even though declining acres in Latin America and North America created headwinds. Sales in our glyphosate business fell 6% due to lower prices compared with a year earlier, as we had expected. A strong volume recovery relative to the same quarter last year nearly made up for that decline. On profitability, EBITDA before special items reached EUR 2.8 billion, at a margin of 36%. The drop from a year earlier stemmed mainly from weaker prices for our glyphosate-based herbicides. We also booked negative currency effects of roughly EUR 90 million, along with continuing inflationary pressures. Now let's turn to our Pharmaceuticals business. The division posted sales growth of 4%, as volumes rose 3% and prices rose 1%. Our launch assets once again delivered especially strong performance. In addition, continued robust development of Eylea and the radiology business helped more than offset headwinds in parts of our mature portfolio. Nubeqa kept up its growth momentum, with gains across all regions, and we are on a good path to treat 70,000 patients and exceed EUR 1 billion in total sales this year.

Wolfgang Nickl

executive
#14

We posted meaningful growth with Kerendia as well, largely because volumes rose considerably in both the United States and China. Volume and price gains kept our Eylea franchise expanding at a healthy pace. Eylea 8 mg made its first sales in Q1, as Bill mentioned earlier, after initial approvals came through in Europe and other countries earlier this year. On Xarelto, sales edged up slightly after a soft quarter a year ago. Generic launches arrived as expected once the compound patent lapsed in further markets, including Canada, at the end of last year. Outcomes of patent disputes in Europe have been mixed. The once-daily patent for Xarelto was upheld in countries such as the Netherlands. Preliminary injunctions against generic manufacturers have been obtained in Germany and other European countries. That said, we faced some setbacks in first-instance rulings in the UK and France as well, and we will appeal those decisions. We will keep taking vigorous action against any infringement of the European once-daily intake patent until it expires. Our full year guidance on Xarelto is unchanged, since we have taken a risk-adjusted approach. Turning to the bottom line, EBITDA before special items rose 8% to EUR 1.2 billion in Q1.

Wolfgang Nickl

executive
#15

R&D spending on early-stage clinical development went up, but costs for advanced-stage programs—like the phase III OCEANIC program for asundexian—declined. We also moved funding away from our mature portfolio toward growth investments in our launch products. On the Pharma margin, foreign exchange currencies had a negative impact of about 100 basis points. Now turning to Consumer Health. Sales there fell by 2% versus prior year levels. The main driver was a 17% drop in our allergy and cold business, which the performance of the other categories could only partially offset. Thanks to the strength of our brands and innovation, we were able to actively manage prices and balance impacts from price elasticity. That said, retailers in the United States kept optimizing their inventory across the industry, which led to volume declines. On top of this, we have also been experiencing a very mild cold and flu season. On the positive side, as we further improve supply and availability of key products and begin rolling out consumer-benefiting innovations such as Iberogast in the United States, we will compensate for the trends seen last quarter. EBITDA before special items came in as expected, at EUR 331 million and a margin of 23.1%.

Wolfgang Nickl

executive
#16

Currency movements hit us to the tune of a negative EUR 46 million. Because we keep a steady focus on managing both costs and prices, we managed to offset most of the sales decline, the cost increases driven by inflation, and the bigger investments we made in marketing our innovative products. Let me turn now to the outlook. According to our most recent forecast, we reaffirm the full year outlook at constant currencies. In Crop Science, we remain well positioned to achieve a fourth consecutive year of growth in our core business and to stay within the range we guided. For our core business, the key vectors we anticipate are higher volumes and pricing in crop protection for corn. That is despite lower planted acres, as I said earlier. For glyphosate, we anticipate lower pricing, partly offset by volume recovery. In Pharmaceuticals, we still expect headwinds on Xarelto to grow over the course of the year, which will likely produce year-on-year sales declines for the division across the next three quarters. Given the first quarter result, we feel comfortable about delivering on the division's full year guidance for 2024. In Consumer Health, we keep making further progress on the supply situation and also stay focused on driving consumption. On top of that, we are bringing new innovation to market.

Wolfgang Nickl

executive
#17

So with that, we intend to get back to growth in Q2 and to speed up growth during the second half of the year. On the right-hand side of this slide, as you can see, we've refreshed our FX estimates using March rates and spot rates. Relative to December and spot rates, we've observed an appreciation of the U.S. dollar. That helps our top line, but it hurts our cost positions to a proportionally larger degree. And, as we've discussed many times, the share of our debt that is denominated in U.S. dollar will take a negative translation hit. Meanwhile, other currencies have depreciated — the Argentine peso, the Turkish lira, and the Japanese yen as well, for example. These latest developments are reflected in the current FX estimates. Reported sales growth stays within the range we gave, because of offsetting dynamics across the currency basket. At the same time, we now forecast a bigger headwind on EBITDA before special items — minus four percentage points, versus roughly minus three percentage points before. That flows through to an FX effect of approximately -EUR 0.30 on core earnings per share. We've also revised our FX estimates for free cash flow to approximately minus EUR 300 million, and for net financial debt to about EUR 500 million.

Wolfgang Nickl

executive
#18

The rest of the modeling assumptions are unchanged from what we guided before, and you can find them in the appendix to this presentation. That brings our prepared remarks to a close, and Jost, I'll turn it back to you so you can take us through the Q&A, please.

Jost Reinhard

executive
#19

Thanks so much, Bill and Wolfgang, for those presentations. We’ll now begin the Q&A session, and I’d also like to invite Rodrigo, Stefan, and Julio, who are with us by video today. Just a few housekeeping notes before we start. If you’d like to ask something, please raise your hand and follow the instructions in the chat. Kindly keep it to two questions per person so we can fit as many participants into the session as possible. Today’s first question is from Emily Field at Barclays. Emily?

Emily Field

analyst
#20

Hello, and thanks very much. Hello, and thank you for taking my questions. I'll keep it to just two. The first is on Xarelto. I was hoping you might give a bit more detail on how the regions performed. Was part of that growth volume gains in China after the softer quarter in the prior-year period? And then I think you mentioned some setbacks in France and the U.S. — could you clarify what those were, and whether that would have hurt guidance negatively versus what was issued at the full year? And second, I know you said free cash flow in the quarter got a boost from the timing of litigation payouts. Was that the main reason you didn't raise that guidance for the full year? Because it did come in quite strong versus our expectations. So perhaps just some thoughts on how free cash flow will be phased over the year. Thank you.

Bill Anderson

executive
#21

Okay, thanks, Emily. Let’s see. I think I’ll have Stefan respond to your question on how Xarelto performed by region. And then, could you clarify—you mentioned France and the U.S., we—

Emily Field

analyst
#22

My apologies.

Bill Anderson

executive
#23

Did you mean Xarelto in particular, or are you asking about the overall picture?

Emily Field

analyst
#24

Yeah, I just had a question — in your prepared remarks, I was hoping you could clear up a few of the comments you made about the setbacks relating to the full year guidance. Could you just explain what you meant by that?

Bill Anderson

executive
#25

Alright, Stefan, please go ahead with Xarelto, and then Wolfgang, you can cover free cash flow.

Stefan Oelrich

executive
#26

Okay, thanks, Emily. So yes, Xarelto is really a mixed picture overall. Let me begin by noting that we're genuinely encouraged that Xarelto still delivered some growth across the first quarter as a whole. And we had kind of expected that at-risk launches would occur in certain regions of the world, and that is now partly playing out. Of course, we are vigorously defending our intellectual property globally, and we believe we will prevail in the end. However, we have encountered some unfavorable court rulings, specifically in France, where generics have now come to market at risk. We are appealing that situation, and a decision on this matter should come at some point during the second half of the year. We also face some difficulties regarding upholding the validity of our patent at first instance, potentially in certain Eastern European nations. But overall, Xarelto is actually holding up quite well during the first quarter. And that includes, by the way, France, where the impact is beginning, as one would expect, following LOE of the NCE patent. So stay tuned. Providing you with significantly more detail is really difficult right now, because we'll essentially need to wait until things settle down somewhat at the end of Q2, and I think at that point we can offer a clearer outlook regarding what this year will look like for Xarelto.

Stefan Oelrich

executive
#27

I believe that's fully addressed within the guidance we've given for Pharma overall.

Wolfgang Nickl

executive
#28

Hi Emily, Wolfgang here. I'll take your question on free cash flow. You're correct. In Q1 of last year, free cash flow came in substantially negative, at -EUR 4.1 billion. This year it was -EUR 2.6 billion, so less negative, which is a meaningful difference. Keep in mind, most of that improvement stems from lower settlement payouts. A year ago we had large PCB payouts, and those didn't occur this year. We clearly anticipated that going into the quarter, so it was baked into our assumptions. On the operational side, we likely did slightly better. As I noted, a few of the working capital initiatives are already delivering benefits, especially on inventory. That's what we observed in Q1. Still, it's too soon to make any changes to our free cash flow outlook. As you can see, we've set a fairly wide range for the full year, including some negative FX impacts. That said, we're definitely pleased with how we've begun the year, and it stays a key priority to support the net financial debt position.

Jost Reinhard

executive
#29

Thanks, Wolfgang. Now we'll take a question from Vincent Andrews at Morgan Stanley. Vincent?

Vincent Andrews

analyst
#30

Thanks. Morning, everybody. Rodrigo, I was hoping you might give us some color on how the spring season is shaping up in the United States. It seems like you did achieve positive pricing in corn. Perhaps you could speak to that a bit. But then on soybeans as well, sales appear flat, yet the slides suggest the U.S. is down somewhat. So is that due to lower volume? And do you expect your volume will be down in soy for the full season, even with potentially higher soybean acres?

Rodrigo Santos

executive
#31

Thank you very much for that question, and good morning from the U.S. side. I appreciate the chance to share a bit more about Crop Science. Before I get specifically to your question, I think we're very confident that the core business will deliver a fourth consecutive year of growth, as Wolfgang mentioned, and that matters a great deal to us. As we discussed at the Capital Market Day, 70 days ago, we had already planned this year to be more moderate than last year's. We came from 10% growth, 6%, 7%, and we guide from 1%-4% on the core. That's driven by the corn price gain we had, but also by our crop protection volume. So specifically to your question, what we're seeing in the U.S. is lower corn planted acres, as we planned, and higher soybean. That's a very important element of Q1, right? We're in the middle of the season in the U.S. We didn't anticipate any sales from Q2-Q1. I saw some of our competitors reporting that. We don't have any anticipation. Just to give you a concrete example, our soybean sales in the U.S.

Rodrigo Santos

executive
#32

Right now, in April, it's very high. So we feel good about the plans we have for the year, with the corn growth we're planning, and also the soybean. On soybean, we came out of last year with 6% growth. We hold the leading position with EUR 2.6 billion. Our second company in the market is at 1.8, and they came in with 3%. We talk about equilibrium in the market, specifically in the U.S., and that's what we're also seeing on the order book. So mid-season in the U.S., we're confident our plans will be executed, as you also heard from Bill and Wolfgang. But with an early start to the year, there's still a lot of work to do this year, not only for North America, as you asked, but also EMEA, and especially in the second part of the year for Latin America and Asia. But the plans are in place, and we're confident in what we have for the year. Thank you.

Vincent Andrews

analyst
#33

Thank you.

Jost Reinhard

executive
#34

Appreciate that, Rodrigo. Our following question is from Peter Verdult at Citi.

Peter Verdult

analyst
#35

Thanks, two seconds. Yeah, thanks. This is Peter Verdult from Citi. I have two questions. Stefan, first one is for you, on the main growth drivers — Nubeqa, Kerendia, and acoramidis. Finerenone and ARANOTE are coming in the second half, and the acoramidis deal was signed just around your CMD. Could I push you to remind us of the sort of ballpark contribution to Bayer's EUR 3 billion plus peak sales guidance for Kerendia and Nubeqa that finerenone and ARANOTE might be giving you? I know an exact number isn't something you can give me, but a ballpark would help. And then also, what do you think you can do with acoramidis in Europe? And then just very quickly for Rodrigo, building on the previous question, apart from weather, what are the key swing factors for crop for the remainder of the year? And you spent the last few quarters being very clear that unlike your peers, you weren't suffering from destocking in the channels, and that's now been called out. So what has changed to make Bayer now call that out as a dynamic to consider for the business? Thank you.

Stefan Oelrich

executive
#36

Hi, Pete, and thanks for asking. As you already kind of expected, it's going to be tough to offer you anything beyond a rough estimate on this one. With Nubeqa, clearly, we're extremely happy. If you look at the first quarter, we crossed, on a 12 month basis, EUR 1 billion. So it's now genuinely a blockbuster in its own right. So that's progressing as well as, or better than, we anticipated. With ARANOTE, we're getting more completeness in our data set. You know, what we're lacking is the middle, for the metastatic setting in Nubeqa alone, so without chemotherapy, and we believe that genuinely fills a significant gap. I'm aware that some folks out there are assuming this will work, but we'll need to confirm it, so it all comes down to the data. That will be a crucial element on our path to peak sales for Nubeqa. On Kerendia, I've mentioned it in earlier quarters, we've been — I think all of us have felt somewhat underwhelmed by how the renal market itself has developed. We benefited disproportionately while the market was rising, and we've watched this come to what is more of a stabilizing marketplace.

Stefan Oelrich

executive
#37

So this is definitely not moving along as quickly as we would have liked, but we see that with a heart failure opportunity, which aligns directly with how an MRA works, we believe we truly have a crucial benefit to offer — always assuming the data plays out — and that will ultimately also let us reach peak sales. For acoramidis, we haven't provided guidance yet, so give me a bit of time on this, but I'm looking at data that looks extremely promising when I compare it with the competition. And the competition is now in Europe alone at more than EUR 1 billion in sales, growing quickly. So I think we're really entering this race at just the right moment, with a very competitive asset and a very competitive commercial footprint. So this is something I'm really looking forward to giving you more detail on as we go along.

Rodrigo Santos

executive
#38

Let me also take up the Crop Science question and how we're planning for the year — naturally, weather effects come into it, and you laid those out very well, such as what happened in EMEA, particularly early in the year, which is pushing the season back somewhat. And what we're seeing right now — in southern Brazil at the moment, of course, that's a significant hit for the growers there as well. But also, when we were thinking about this year — USDA just reported last week, right? — so farmers this year are going to receive a lower commodity price payout than the prior year. That's why we saw a moderation for the year. Again, prices are still above the 10 year average, but it's a moderation relative to the last two years that we saw in the market. So that's what we planned for, for the full year, and that's why, again, the operational excellence you mentioned regarding how we manage our inventory in the channel is helping us deliver another growth at the core. We're going to see it already in Q2 — we are planning for low double single-digit growth in Q2 — and we also have growth planned for the Southern Hemisphere in the second half of the year, driven by crop protection volumes.

Rodrigo Santos

executive
#39

Once more, we saw no significant effect from what you’ve picked up in the market, and you also brought up stocking by our competitors, plus our main corn and soy business in Latin America during the second half of the year. That’s going to support the plan for the year. So it’s a somewhat more moderate year. We’re monitoring it closely. A lot of diligent execution is needed this year. We’re obviously keeping an eye on the weather events occurring right now, a very dynamic market as is typical for Crop Science. We’re still tracking very closely what’s going on in southern Brazil and, again, in EMEA, the April, May sales will be an important execution as well. But I just want to underscore what you said. I’m proud of how our organization has executed, on operational excellence, on the way we’re managing our business, our core business with the, with the sales in the market. Thanks for the question.

Peter Verdult

analyst
#40

Thanks.

Jost Reinhard

executive
#41

Our next question is from Richard Vosser at J.P. Morgan. Richard?

Richard Vosser

analyst
#42

Hi, thanks for taking my questions. Perhaps I could just follow up on those remarks, Rodrigo, regarding low single-digit growth for the crop business in Q2. Just thinking about herbicides outside of glyphosate, you know, a very quite weak performance in Q1, talking about delayed decision making. Should we expect a recovery in 2Q? Because you have quite an easy comp last year, so just the low single digit seems a little bit maybe conservative. Then fungicides as well, you know, a recovery in sales in Q2, weak Q1, should we get a catch up in Q2? Is would be a question. So those, those two questions, and then maybe if I can if they count as one, maybe one on reconciliation, 'cause it's a little bit dull. Just, you know, about the guidance, you've got the long-term incentive plan adjustments in Q1, but why not take the EUR 500 million cost lower for the rest of the year? Thanks.

Rodrigo Santos

executive
#43

Okay, so let me go ahead, and then Wolfgang, I'll hand things over to you, I suppose, correct? So to get at your question, I'd say the main factor for Q2 is going to hinge on EMEA, correct? In EMEA, in Europe, we experienced that seasonal delay caused by the weather event, hitting exactly what you mentioned, correct? The herbicides as well as the fungicide market, glyphosate excluded. So we are going to, we are going to see—we're seeing Aprils, and we're going to keep monitoring Q2. We believe this is the right plan we currently have in place. For the full year, we do expect—not just in EMEA but across the rest of the globe too—we expect higher volumes in our crop protection business, correct? We've stayed very disciplined about managing inventory on the channel, and there's a solid opportunity for us in the second half of the year too. And regarding EMEA specifically, we're going to see how it turns in Q2. That's why we feel confident in our guidance of 1%-4% growth at the core for the year, and we're going to keep executing on that. So that's an important point. You just brought it up, but let me elaborate a bit on glyphosate, since I think that matters too, correct?

Rodrigo Santos

executive
#44

Regarding pricing, we’re making Q1 versus Q1 of last year comparisons. For Q2, Q3, and Q4, that isn’t what we expect. I believe our guidance for glyphosate this year is solid. We also anticipate some volume growth for glyphosate in Q2 compared with last year. So that will factor into the dynamics we’re planning for the second quarter and the full year. Thank you. Wolfgang?

Wolfgang Nickl

executive
#45

Richard, I’ll walk through the reconciliation, and it’s probably helpful for everyone listening if I spell out exactly what sits inside it. First, the reconciliation is made up of cost items that simply can’t sensibly be allocated to central cost. Second, it contains a number of very, very small businesses that aren’t really material to the company as a whole, and it certainly includes technical effects that we book there, since allocating them would be very complicated or would distort how the divisions look. Those last two are where we’re seeing the impact in Q1. We guided to a full-year reconciliation of -EUR 500, so you could assume -EUR 125 each quarter, and your question is completely fair. If we’re at +EUR 38 in Q1, why doesn’t that carry through to the full year? The impact came from the two items I just mentioned, LTI and other technical effects. LTI is heavily driven by the share price, among other things, and when we closed the quarter, last quarter, it stood at around 100- ... 25. We hope it won’t be there at year-end. It certainly isn’t there today, so that’s the only cost pickup that I really like when it’s driven by a share price.

Wolfgang Nickl

executive
#46

The second item involves certain hedging and hyperinflation accounting entries — tied to places like Argentina, for example — which arrive with a time lag and don't show up in either division. And on top of that, the Argentinean peso is extremely volatile. So, in brief, it's too soon to make a call on the full year. We're pleased with how the year has begun, especially on the hyperinflation side, and we'll let a bit more time pass, then revisit it in Q3, and we'll provide an update in Q once we believe things have firmed up. I hope that's useful to you, even though the answer ran a little long.

Richard Vosser

analyst
#47

Thanks.

Jost Reinhard

executive
#48

And that takes us to the following question, which comes from Joel Jackson at BMO.

Joel Jackson

analyst
#49

Good morning, good afternoon. Can you hear me?

Jost Reinhard

executive
#50

Yes, we’re able to do that.

Joel Jackson

analyst
#51

Thanks, and apologies for that. I’ll ask a couple of questions, one at a time. Maybe to start at a high level: now that you’re really pushing ahead with the DSO and the new operating model, could you share some examples of what’s been quick to capture? Which parts have proved simplest to put in place? And what have you found that might be the toughest? Perhaps you could offer a few lessons you’ve picked up so far, early in this process—that would be useful.

Bill Anderson

executive
#52

Yeah, good question — and I’ll ask my colleagues to jump in with anything they’ve got. I think, you know, we found a handful of things where we told ourselves, plainly, that we’re capable of doing them better — fairly basic stuff. For example, we were running operational audits, and we just said, “Hey, we don’t do that.” A lot of us have spent the bulk of our careers at companies where that concept doesn’t even exist — you know, having a department whose job is to go check whether other departments are, you know, doing their work properly, which isn’t the same as an audit for, you know, fraud or compliance. So that kind of thing. We had a big strategy group, and we said, “Hey, you know, under our new model, we believe strategy belongs to everyone in the company.” You know, if you’re supporting a customer, then the strategy with that customer is your job. If you’re building products, that’s your job. We don’t need a separate department handling that. And so, you know, there were a few items along those lines. I think probably, you know, maybe for some of the other stories I’d turn it over to our colleagues.

Bill Anderson

executive
#53

I’m turning to the division heads here. What easy wins have you all identified?

Rodrigo Santos

executive
#54

I can begin there, Bill. That's an excellent question, since we discussed this extensively at the capital market day, 70 days. Full execution is where we stand. That's the main point I want to convey. In Crop Science, we designed the operating model that truly fits that purpose, and it centers heavily on product teams along with customer-facing teams. As you heard earlier, we are right now rolling out all the customer teams across the Americas, and we're extending into EMEA and Asia in Q2. Come Q3, we will have over 450 customer-facing squads working alongside our farmers. We'll also have our Product Supply, R&D organization, and a substantial portion of our Enabling Functions included. So full execution of this is underway. One of the main things I'd say I want to emphasize, given your question about lessons learned, is how sharply we're concentrating on gaining more customer-facing time, delivering better quality service to our customers, and generating more innovation. Regarding the R&D design, it was tightly aimed at freeing up resources and delivering considerably more innovation to our organization. So we're in execution mode at present, with plenty of work, and you'll certainly hear far more from us in 90 days.

Rodrigo Santos

executive
#55

But Stefan, I'll hand it over to you.

Stefan Oelrich

executive
#56

Sure. Thanks. Thanks, Rodrigo. So, building on that a bit, Joe, I think what we’ve observed—and this isn’t precisely what you asked, but it might address it somewhat—is that all of us have been surprised by how quickly and enthusiastically the system has been implemented. Pursuing a model that is far more customer- and product-focused resonates readily with many people within the company. So in our Customer-Facing Units in Pharma, where we’ve rolled it out, such as in the U.S., I believe we’ve found no major hurdles during implementation. And honestly, in Pharma, field force realignments tend to happen fairly regularly. So that isn’t what’s slowing us down. It’s how we operate—making decisions faster and delegating decision-making authority more to the Customer-Facing Unit itself. So I think that’s progressing well. In other countries, where things may be moving somewhat more slowly, that’s due to local regulations that demand extensive consultation before implementation. But again, nothing unusual. I think the bigger shift occurs in how we organize and structure our global units, where we now do what we call tilt the pyramid, moving from a hierarchy driven very much by function to an organization that is more product-centric.

Stefan Oelrich

executive
#57

When it comes to Pharma, what we're doing is constructing dozens of speedboats, and we're drawing on a few of our biotech acquisitions that were held at arm's length and operated fairly independently. Those serve as blueprints for applying this approach to our big products and big priorities, but also to the smaller ones in development or, shall we say, the foundational products, running them truly as micro-enterprises. I think that's something I'm genuinely eager to find out whether it will turn into gaining momentum, into fostering that sense of ownership. And ownership has two sides to that coin: greater freedom to act, but likewise greater responsibility and accountability for results. So, it's something I could see generating a lot of enthusiasm, yet also some disruption, since it brings change to our organization.

Julio Triana

executive
#58

Stefan, and maybe the guys, if I could just give one example from Consumer Health. Essentially, in the same vein as what my colleagues said, in Consumer Health we have launched roughly 90 teams so far — customer teams as well as product teams — around the world. But let me just call out one example we have in ASEAN. In that region, we're heavily indexed in nutritional, so a big portion of our portfolio sits in nutritionals, and the team wanted to find out whether they could diversify and bring some of the other brands that are doing well in other parts of the world into ASEAN. So we let the team examine what the local options were, and what they actually came up with was that by negotiating with a local contract manufacturing operation, they could cut the amount of launching cosmetic products like, you know, Bepanthen and also Claritin. They took this from 36 months down to roughly 9 months. Now, the power of that isn't only what happened in ASEAN, but the scalability we can achieve with this kind of approach across the world. So just to give you another example of how we're leveraging DSO.

Julio Triana

executive
#59

That should be useful, I hope.

Bill Anderson

executive
#60

Appreciate it, folks. You wanted to know what’s toughest, and I’d point to a couple of cases that demand a bit more work. Take some of our Enabling Functions: redesigning an enabling function is really difficult until you understand the architecture of the business it’s meant to support. So we have folks eager to move and genuinely excited about doing it, but it’s kind of like, well, we need a bit more detail from the businesses about precisely what will work best to support their new architecture. That’s one case. Another case is the setup we’re choosing. It calls for, say, plenty of peer feedback and peer evaluation, since if you go from a span of control of, say, five, six, seven, to what we call a span of coaching, which can reach one manager for 20 people or even 30 people, then the old approach won’t work. A manager can’t be writing performance assessments for 30 people. That simply falls apart. So you truly need systems that gather data from peers and deliver, well, summaries and that sort of thing.

Bill Anderson

executive
#61

And so we’re moving in that direction, but building a system of that kind for a company with close to 100,000 people isn’t something you do in weeks. It takes a bit more time. So those are instances of some of the items that require a little more effort.

Joel Jackson

analyst
#62

Alright, thanks for that. Now to my second question. This one is likely directed at Rodrigo. From an outsider's perspective, things have seemed really quiet regarding dicamba following, you know, what took place a few months back. Perhaps you could tell us, you know, what sorts of discussions are taking place? Sorry, what discussions are you currently having? What is the route ahead to attempt to restore dicamba to a normal situation for next year? And while all of this is happening, you've got your strategy, what type of seeds you produce, with which traits, and how you handle your contract growers, where they actually grow, and have you altered anything as you look toward this year's growing season for next year's sales? For instance, maybe walk us through what's happening internally and externally that could bring this somewhat back to normal, whatever that might mean?

Rodrigo Santos

executive
#63

That's a key point. Thank you very much for raising that question. A great deal of work is happening externally, and internally as well, I would say. We're collaborating extensively with EPA. We submitted the—a new herbicide. It's public now that we're seeking approval for this new herbicide, which has pre-applications on soybean and takes a different approach for cotton too. So we're fully engaged with EPA for the next season, and as you mentioned, there's a lot of backing from the farming community. I don't need to stress how important that is, and growers are conveying how important it is for that system to arrive sooner for that one. Of course, we're working on it. We also have plans in place regarding what we are—the production, as you mentioned, some other plans we have— ... to address the next season. This will matter for Q4 of this year, but mainly, mainly for 2025, right? And that's exactly what you said. So we're confident in the plan we have, working with EPA to secure the registration of this new herbicide and to deliver that to farmers for the next season. So a lot of work is going on right now.

Rodrigo Santos

executive
#64

At the same time, there’s a great deal of effort going into the other plans we’ve put in place for the coming season. And likely in Q2 or Q3, we’ll share many more details about that. But a lot of work is underway right now, as we speak here.

Joel Jackson

analyst
#65

Thank you.

Jost Reinhard

executive
#66

Thanks, Rodrigo. We’ve got two additional raised hands in the chat, and the first is Florent Cespedes from Société Générale. Florent?

Florent Cespedes

analyst
#67

Good afternoon, and thanks. This is Florent Cespedes from Bernstein. I appreciate you taking my questions. I have two quick ones. First, for Stefan: could you give us a bit more detail on what's driving Eylea? Is it mostly the new formulation, and some insight into the trend and the main territories would be great. My second question, on consumer for Julio: could we get more color on how the rest of the year will play out when it comes to inventories? You mentioned there will be new products, so more detail by the main businesses would be great. Thank you.

Bill Anderson

executive
#68

Okay, Stefan, go ahead and speak to the Eylea outlook, if you would. And Florent, I wasn't clear on the inventories — were you referring to Pharma, or—

Jost Reinhard

executive
#69

Consumer health.

Bill Anderson

executive
#70

Consumer Health. All right, understood.

Florent Cespedes

analyst
#71

No, my apologies — that's consumer and consumer.

Bill Anderson

executive
#72

Understood.

Florent Cespedes

analyst
#73

Absolutely.

Bill Anderson

executive
#74

Got it. Thanks. Thanks. Stefan, go ahead.

Stefan Oelrich

executive
#75

Thanks, Florent. Yeah, we're quite pleased with how Eylea is performing, and in most of our territories, and the 8 milligrams doesn't really have a major role yet in any of our territories. We've launched this in Germany, so it's going to be a gradual launch, as we clear market access hurdles around the world. So far, so good, by the way, on that front. What we're seeing is that we haven't really been hit much by competitor entry in the space, so we've continued to increase both, especially in volumes, and also maintain price across our Eylea franchise pretty much around the world with some negatives, but overall, very positives. And what we're seeing is that competition mostly takes away share from Lucentis and much less so from Eylea. Again, there are very few exceptions that confirm that rule, but overall, a positive picture. And we think that with the 8 mg, we're going to have an even more favorable dynamic. So stay tuned how this works out pricing-wise. You know that we have assumed a parity pricing to the low dose or to the 2 milligrams of Eylea. Hopefully, we can even surprise a little positively on that side.

Stefan Oelrich

executive
#76

Overall, the picture seems fairly positive, at least based on what the first quarter shows us. Thanks, Florent.

Bill Anderson

executive
#77

Julio?

Julio Triana

executive
#78

Thanks, Florent. Yeah, Florent, I really appreciate the question, and I'll keep it brief since we're near the end of the call. So our confidence in the outlook for the rest of the year is unchanged. As you know, we guided to 3%-6% c.p.a. growth for the entire year, and our EBITDA margin will continue at around 23%-24%. So our guidance stays intact. The supply situation is improving as we move through the year. The innovation launches are going well. For example, with our launch of Iberogast in the U.S., we've been able to almost double the size of the product between Q1 of last year and this quarter. The other topic you mentioned about the inventories, you probably saw it from our competitors. Pretty much, everyone is sort of normalizing the levels of inventory after the COVID pandemic. We expect that the same impact that we saw in Q1 will remain for Q2, but in the second half of the year, this will normalize, and that is included in our confirming the guidance. Overall, we believe that we are in good shape. We should be able to do that.

Julio Triana

executive
#79

Our attention is on boosting consumption globally, though particularly in North America. We'll keep picking up market share with the main products we offer around the globe. I hope that answers your question, Florent.

Florent Cespedes

analyst
#80

Yes, thanks a lot.

Julio Triana

executive
#81

Thanks a lot.

Florent Cespedes

analyst
#82

That’s really useful. Thanks.

Jost Reinhard

executive
#83

That brings us to our final questions, and they come from Sachin Jain at Bank of America.

Sachin Jain

analyst
#84

Sachin Jain here from Bank of America. Thanks for taking my questions. This is a broad-picture question about litigation. So, Bill, I appreciate your opening remarks regarding the progress. I was simply hoping to get a feel for what news flow is expected next at a high level, on both PCB and glyphosate. So, specific questions on PCB: Are there any timelines you can share, and how the Erickson appeal victory applies to the wider litigation? Also, are there any additional appeal decisions in Sky Valley that could have a positive or negative influence? And then regarding glyphosate, I wonder whether you could just address the Missouri state decisions on labeling and whether you still believe, separately, that there's a route to a split circuit. Thank you.

Bill Anderson

executive
#85

Okay, so perhaps I'll address the second question first, and then I'll have Wolfgang weigh in on PCBs. So let's see — regarding the impact, Sachin, we're simultaneously pursuing quite a few different approaches, and which one will prove most impactful is not something we're certain of. Our suspicion is that it will likely be some combination of them. And so this includes continuing, you know, to press very forcefully with the litigation, defending the actions we've taken as well as the safety of our product. In the Carson case, we have the makings of a circuit split that sort of unfolded at the appeals level. But, you know, we have a separate case working its way through another circuit, and so should those come out in different places, then a circuit split exists, and that, you know, presents an opportunity for further escalation. That could matter a great deal. At the same time, we're quite active on the communications front. This is, you know, engaging with farming groups and other concerned groups and individuals in the U.S. And that has generated far more attention over the last 90 days than we've seen at any point in the last few years, including movement in state Houses in three states.

Bill Anderson

executive
#86

And actually, we got at least one chamber of the legislature to pass it in both Iowa and Missouri. In Missouri it’s still in progress, but this concerns legislation that would make clear the EPA label is the label for the land, and really reaffirm the role of a single label and label clarity, which we believe matters a great deal to farmers. For Bayer on glyphosate it matters, but it also matters for the future of innovation in agriculture. We know legislative solutions typically don’t arrive quickly, but we feel it’s the right thing to pursue, and we’ll see how and how long it takes and when we could get such progress. But there’s also a Farm Bill at the U.S. level that would cover, you know, all of the U.S., and that’s another approach. Whether that’ll happen this year or not, that’s a little harder to call. So those are some of the things going on, on the glyphosate side. And maybe, Wolfgang, if you want to comment about PCBs?

Wolfgang Nickl

executive
#87

I'll be brief since we already covered this in the prepared remarks, Sachin. To start, let me repeat that we've discussed Erickson on each of the last three, four, five calls. Now we have it, and it's quite favorable. As you may remember, in that school district, nine cases were tried, and eight ended in adverse verdicts against us. And the appeals court's findings cross-read very solidly into the remaining cases. So I consider that positive. Schedules and timelines are hard to pin down, since courts set cases and then reset them. At present, only two cases appear on the roster for this year. One is in Sky Valley. We'll see how that one goes. Then there's another, involving one of the dropout cities in the class, that we settled, and it's also in the summer. But we'll have to see how that goes. At this point, we're pleased with the result in the Erickson case. Thanks for your question.

Jost Reinhard

executive
#88

All right. That brings our question-and-answer portion to a close, along with today's call. Thanks for spending your time with us and for your interest — have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.